Treatment of chronic hepatitis C infection in patients with renal failure

Paul Martin, Fabrizio Fabrizi

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Patients with end-stage renal disease continue to have a high prevalence of hepatitis C virus infection despite screening of blood products and efforts to prevent the transmission of viral hepatitis within dialysis units. Although biochemical dysfunction often is absent in infected patients, an increased rate of mortality from liver disease has been observed in patients on long-term dialysis. In addition, hepatitis C-infected renal transplant recipients have diminished patient and graft survival rates compared with uninfected controls. Antiviral therapy with interferon in renal transplantation candidates has resulted in sustained viral responses that have been durable even after subsequent renal transplantation. Graft dysfunction remains a major concern, limiting the use of interferon after renal transplant. Ribavirin, which accumulates and cannot be removed by dialysis, and may induce hemolysis, generally has been avoided in patients with end-stage renal disease. In pilot studies, cautious use of reduced doses of ribavirin has been possible in this population with close monitoring of hematocrit levels and additional measures to enhance compensatory erythropoiesis.

Original languageEnglish (US)
Pages (from-to)S113-S117
JournalClinical Gastroenterology and Hepatology
Issue numberSUPPL. 2
StatePublished - Oct 2005
Externally publishedYes

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Treatment of chronic hepatitis C infection in patients with renal failure'. Together they form a unique fingerprint.

Cite this